User login
Key clinical point: Risk classification at acute myeloid leukemia (AML) diagnosis predicted clinical outcomes in patients with or without KMT2A-rearranged AML who underwent allogeneic hematopoietic cell transplant (HCT) in the first complete remission (CR1).
Major finding: Transplanted patients with KMT2A-rearranged and adverse-risk AML had worse overall survival (hazard ratio [HR] 1.32, and HR 1.45; both P < .001, respectively), leukemia-free survival (HR 1.26; P = .002, and HR 1.47; P < .001, respectively), and relapse (HR 1.27; P = .01, and HR 1.71; P < .001, respectively) vs. patients with intermediate-risk AML.
Study details: This retrospective registry-based study included 3,779 adult patients with KMT2A-rearranged (n = 426), non-KMT2A intermediate-risk (n = 2,384), or non-KMT2A adverse risk (n = 969) AML who underwent HCT in CR1.
Disclosures: This study was funded by Weinberg Family and Mortimer J. Lacher fellowships, American Society of Clinical Oncology Young Investigator Award, National Institutes of Health K12 Paul Calabresi Career Development Award for Clinical Oncology, and others. Some investigators reported receiving personal fees, grants, nonfinancial support, research collaboration, owning stocks, or other relations with various sources including pharmaceutical companies not connected with this study.
Source: Menghrajani K et al. Blood Adv. 2021 Sep 22. doi: 10.1182/bloodadvances.2021004881.
Key clinical point: Risk classification at acute myeloid leukemia (AML) diagnosis predicted clinical outcomes in patients with or without KMT2A-rearranged AML who underwent allogeneic hematopoietic cell transplant (HCT) in the first complete remission (CR1).
Major finding: Transplanted patients with KMT2A-rearranged and adverse-risk AML had worse overall survival (hazard ratio [HR] 1.32, and HR 1.45; both P < .001, respectively), leukemia-free survival (HR 1.26; P = .002, and HR 1.47; P < .001, respectively), and relapse (HR 1.27; P = .01, and HR 1.71; P < .001, respectively) vs. patients with intermediate-risk AML.
Study details: This retrospective registry-based study included 3,779 adult patients with KMT2A-rearranged (n = 426), non-KMT2A intermediate-risk (n = 2,384), or non-KMT2A adverse risk (n = 969) AML who underwent HCT in CR1.
Disclosures: This study was funded by Weinberg Family and Mortimer J. Lacher fellowships, American Society of Clinical Oncology Young Investigator Award, National Institutes of Health K12 Paul Calabresi Career Development Award for Clinical Oncology, and others. Some investigators reported receiving personal fees, grants, nonfinancial support, research collaboration, owning stocks, or other relations with various sources including pharmaceutical companies not connected with this study.
Source: Menghrajani K et al. Blood Adv. 2021 Sep 22. doi: 10.1182/bloodadvances.2021004881.
Key clinical point: Risk classification at acute myeloid leukemia (AML) diagnosis predicted clinical outcomes in patients with or without KMT2A-rearranged AML who underwent allogeneic hematopoietic cell transplant (HCT) in the first complete remission (CR1).
Major finding: Transplanted patients with KMT2A-rearranged and adverse-risk AML had worse overall survival (hazard ratio [HR] 1.32, and HR 1.45; both P < .001, respectively), leukemia-free survival (HR 1.26; P = .002, and HR 1.47; P < .001, respectively), and relapse (HR 1.27; P = .01, and HR 1.71; P < .001, respectively) vs. patients with intermediate-risk AML.
Study details: This retrospective registry-based study included 3,779 adult patients with KMT2A-rearranged (n = 426), non-KMT2A intermediate-risk (n = 2,384), or non-KMT2A adverse risk (n = 969) AML who underwent HCT in CR1.
Disclosures: This study was funded by Weinberg Family and Mortimer J. Lacher fellowships, American Society of Clinical Oncology Young Investigator Award, National Institutes of Health K12 Paul Calabresi Career Development Award for Clinical Oncology, and others. Some investigators reported receiving personal fees, grants, nonfinancial support, research collaboration, owning stocks, or other relations with various sources including pharmaceutical companies not connected with this study.
Source: Menghrajani K et al. Blood Adv. 2021 Sep 22. doi: 10.1182/bloodadvances.2021004881.